The Contact Activation Cascade: Four Targets, One Disease

Hereditary angioedema (HAE) is caused by deficiency or dysfunction of C1-esterase inhibitor (C1-INH, encoded by SERPING1), which removes the brake from the plasma contact system and allows uncontrolled bradykinin production. The cascade begins with Factor XII (FXII/F12, the Hageman Factor) autoactivating upon contact with negatively charged surfaces, proceeds through Factor XIIa (FXIIa)-mediated conversion of prekallikrein to active plasma kallikrein (pKal), and culminates in cleavage of high molecular weight kininogen (HMWK) to generate bradykinin — a vasoactive peptide that activates B2 receptors on vascular endothelial cells, increasing permeability and producing the characteristic episodic swelling.

Patent filings from Takeda/Dyax describe a critical positive feedback amplification loop: FXIIa activates prekallikrein, and active pKal in turn further cleaves F12 — creating a self-amplifying cycle that explains why blocking the active form of pKal is mechanistically distinct from blocking the zymogen. This feedback rationale is the foundation of the anti-pKal antibody strategy. According to WIPO, rare disease patent filings have grown substantially over the past decade, and HAE represents one of the most densely patented rare inflammatory conditions.

The four primary molecular targets identified across retrieved patent filings are: KLKB1/prekallikrein (the most heavily patented target in this dataset, addressed by antibodies, small molecules, ASOs, and RNAi); F12/Factor XII (targeted both by antibody and RNAi, and implicated in HAE type III via gain-of-function mutations); KNG1/kininogen-1 (included in Alnylam’s tri-target RNAi strategy as the substrate for bradykinin generation); and SERPING1 (C1-INH, approached exclusively through upregulation rather than inhibition, reflecting the disease mechanism of C1-INH deficiency).

Monoclonal Antibodies and Oral Inhibitors: The Commercial Core of the HAE Pipeline

Anti-plasma kallikrein monoclonal antibodies constitute the largest patent cluster in this dataset, with Takeda Pharmaceutical Company Limited (successor to Dyax Corp.), Astria Therapeutics, and CSL Innovation holding the dominant positions. The critical structural insight common to all leading antibodies is that they must bind the active form of pKal — not the zymogen prekallikrein — to be therapeutically effective. This selectivity requirement is specified across multiple Takeda/Dyax filings and underpins the mechanistic rationale for targeting pKal at the point of its enzymatic activity.

Lanadelumab (DX-2930): The Established Prophylactic Standard

Lanadelumab (marketed as Takhzyro) is characterized structurally in Dyax Corp. and Takeda patents by heavy chain CDRs 1-3 (SEQ ID NOs 5-7) and light chain CDRs 1-3 (SEQ ID NOs 7-10). Takeda’s Australian patent filings explicitly reference results from clinical studies demonstrating that doses of 30 mg, 100 mg, 300 mg, and 400 mg every two weeks showed effectiveness in preventing HAE attacks, with no dose-limiting toxicity observed. Prophylactic dosing is specified at 300 mg every two weeks or 300 mg every four weeks, with the pharmacokinetic rationale that maintaining plasma concentrations above 80 nM is sufficient for prophylactic effect; dosing at 300 mg every two weeks maintains steady-state concentrations above 200 nM. Normalization of kininogen biomarker instability is used as a pharmacodynamic endpoint across filings. Patient subpopulations addressed include female patients, pediatric patients under 18 years, adolescents, and patients with prior laryngeal attacks or high baseline attack rates.

“Maintaining plasma lanadelumab concentrations above 80 nM is sufficient for prophylactic effect — dosing at 300 mg every two weeks maintains steady-state concentrations above 200 nM, providing a substantial pharmacokinetic buffer.”

STAR-0215 (Astria Therapeutics): Extended-Interval Differentiation

Astria Therapeutics is prosecuting a separate anti-pKal antibody portfolio for STAR-0215, with 2024 US and 2025 WO patent filings specifying dosing regimens that feature an initial loading dose of at least 450 mg followed by extended-interval maintenance dosing. The defined clinical outcome measure — attack-free periods of at least three to six months from treatment initiation — signals this asset is in clinical trials and is pursuing competitive differentiation against lanadelumab’s biweekly or monthly dosing schedule. According to FDA guidance on rare disease drug development, extended-interval dosing can be a meaningful differentiator for patient burden and adherence in chronic prophylaxis settings.

Garadacimab (CSL Innovation): Upstream Factor XII Targeting

CSL Innovation’s anti-Factor XII antibody garadacimab represents a mechanistically differentiated approach within the antibody modality, targeting upstream FXII rather than active pKal. Its patent specifies subcutaneous administration, aligning with prophylactic intent. This upstream positioning means garadacimab blocks the cascade before prekallikrein conversion, which may offer a broader suppression of contact pathway activation but sacrifices the specificity of targeting only the active kallikrein form.

Sebetralstat (KalVista): The Oral On-Demand Option

KalVista Pharmaceuticals is the primary driver of oral small molecule innovation in this dataset. Sebetralstat — an oral, on-demand plasma kallikrein inhibitor — is covered in two 2025 WO filings that frame it specifically as on-demand treatment for severe or very severe HAE attacks in patients also receiving prophylactic therapy, including prophylaxis with FXIIa inhibitors such as garadacimab. The 2025 filings reference the PGI-S (Patient Global Impression of Severity) scale for characterizing attack severity and name comparator prophylactics including garadacimab, STAR-0215, donidalorsen, and deucrictibant — indicating awareness of the full competitive clinical landscape. Earlier KalVista chemistry patents cover the medicinal chemistry foundation: N-((het)arylmethyl)-heteroaryl-carboxamide compounds, bicyclic plasma kallikrein inhibitors, and benzylamine derivative series.

RNAi and Antisense Oligonucleotides: Durable Contact Pathway Silencing

Nucleic acid medicines targeting the HAE contact pathway represent the most ambitious prophylactic strategy in the pipeline: rather than blocking an active protein, they suppress its production at the mRNA level, aiming for durable, deep knockdown with extended dosing intervals. Two distinct nucleic acid modalities — RNA interference (RNAi) and antisense oligonucleotides (ASOs) — are active in this space, with Alnylam Pharmaceuticals and Ionis Pharmaceuticals as the respective lead assignees.

Alnylam’s Multi-Target RNAi Strategy

Alnylam Pharmaceuticals has filed the most extensive RNAi patent portfolio in this dataset, covering double-stranded RNAi agents targeting all three genes in the contact amplification cascade: KLKB1, F12, and KNG1. Filings span multiple jurisdictions — WO, CA, AU, EP, HK, UY — with filing dates from 2016 to 2024, indicating sustained and expanding IP prosecution activity. The multi-target approach is mechanistically significant: simultaneously silencing KLKB1, F12, and KNG1 aims to suppress the contact cascade at multiple nodes with a single therapeutic agent, eliminating the feedback amplification loop rather than simply blocking one component. AdarX Pharmaceuticals has also filed on prekallikrein-modulating compositions targeting PKK mRNA, expanding the competitive landscape for RNAi-based KLKB1 knockdown.

Ionis and ISIS 721744: Named Compound ASO Program

Ionis Pharmaceuticals (formerly ISIS Pharmaceuticals) has filed multiple patents covering ASO-based reduction of prekallikrein (PKK) RNA, protein, and activity. The lead compound ISIS 721744 is specifically named as the active agent in multiple filings across US, IL, AU, BR, and WO jurisdictions. Ionis filings describe a loading-dose/maintenance-dose regimen — loading doses every approximately two weeks, followed by maintenance doses every five to nine weeks — consistent with the pharmacokinetic profile expected for a subcutaneously administered, liver-targeting ASO. The therapeutic application spans HAE and macular edema, reflecting the broader role of plasma kallikrein in vascular permeability. Earlier ISIS Pharmaceuticals filings from 2012 to 2014 established the foundational KLKB1 antisense concept across WO, CA, AU, and EP jurisdictions. Research published by Nature has documented the growing role of liver-targeted ASO and RNAi platforms in rare metabolic and inflammatory diseases, providing translational precedent for this approach in HAE.

The strategic implication for both ASO and RNAi programs is that translation from liver-targeted approaches to HAE-relevant tissues will be a key de-risking milestone. Liver-targeting delivery platforms are well established for both modalities — consistent with KLKB1 and F12 being predominantly hepatically expressed — but clinical validation in HAE specifically remains to be demonstrated for these programs based on available patent signals.

Gene Therapy and RNA Activation: Targeting Root-Cause Restoration of C1-INH

The most forward-looking segment of the HAE pipeline aims not to block a downstream target but to restore the deficient protein at its source — either by re-expressing C1-INH through cell-based gene therapy or by activating the endogenous SERPING1 gene using small activating RNA. These approaches are qualitatively distinct from all other modalities in that they target root-cause correction rather than pathway suppression.

Orchard Therapeutics: Pluripotent Cell-Based C1-INH Expression

Orchard Therapeutics (Europe) Limited has filed patents describing compositions and methods using pluripotent cells engineered to express C1-INH to treat or prevent HAE. Patent filings in IL and other jurisdictions date to 2023, suggesting active development. This approach represents a potential one-time or durable cell-based intervention analogous to gene therapy strategies in other rare diseases — correcting the upstream genetic deficiency rather than targeting downstream pathway components. The clinical development path for such an approach will require demonstration of durable C1-INH expression and safety of the cell engineering platform, representing substantial but potentially transformative development risk.

Ractigen Therapeutics: Small Activating RNA for SERPING1 Upregulation

Ractigen Therapeutics filed a 2024 WO patent covering small activating nucleic acid molecules (saRNA) that target promoter regions of SERPING1 to upregulate C1-INH gene expression. The sense and antisense strands are 16 to 35 nucleotides in length with at least 75% base homology or complementarity to the SERPING1 promoter. This RNA activation (RNAa) mechanism — which activates rather than silences gene expression — is the most mechanistically novel approach in this dataset. Rather than replacing or supplementing C1-INH protein, saRNA aims to restore endogenous expression by engaging the cell’s own transcriptional machinery at the promoter level. The NIH has recognized RNA activation as an emerging therapeutic modality with potential applications across rare genetic diseases where gene upregulation rather than silencing is the therapeutic objective.

F12 Gene Therapy: Early Conceptual IP

Multiple patents from Georg Dewald (filed 2005 to 2016 across WO, EP, CA, US, IN, and ES jurisdictions) address diagnostic methods for HAE type III via F12 mutation detection and explicitly scope gene therapy methods as part of the invention. These filings establish early conceptual IP linking F12 gain-of-function mutation identification to gene-level therapeutic intervention, though the Dewald filings are largely diagnostic and conceptual in nature rather than representing active therapeutic development programs.

IP Strategy and Competitive Dynamics Across the HAE Pipeline

The HAE patent landscape is shaped by several intersecting strategic forces: lifecycle management by the established commercial leader, oral access as a white space being actively filled, combination regimen IP as an emerging battleground, and gene-level correction approaches that remain early but represent the only paths to potential cure. Understanding these dynamics is essential for freedom-to-operate analysis, competitive intelligence, and pipeline positioning.

Takeda/Dyax: Layered Lifecycle Management

The high volume of continuation, divisional, and jurisdiction-extension filings by Takeda/Dyax for lanadelumab-related IP — spanning AU, IL, NZ through 2025 — indicates active efforts to extend commercial IP protection well beyond the original priority dates of 2014 to 2016. This creates a layered, multi-jurisdictional patent estate that will require careful freedom-to-operate analysis for competing programs. Takeda’s 2020 CA patent on quantitative systems pharmacology (QSP) modeling for HAE — incorporating virtual patient populations and contact system dynamics models — signals use of in silico methods to accelerate dose optimization and virtual trial design, a translational capability that reinforces the depth of the Takeda/Dyax IP position. The EMA has increasingly recognized model-informed drug development as a tool for optimizing dosing in rare disease populations, lending regulatory relevance to this QSP filing.

Oral Modality: KalVista’s Defensive Coverage Strategy

Sebetralstat, the only oral on-demand pKal inhibitor in this dataset with named compound and clinical-context claims, addresses a significant patient preference and access gap relative to injectable biologics. KalVista’s IP strategy around formulation (modified-release) and combination use claims in 2023 to 2025 filings suggests active construction of defensive coverage around the oral modality. Critically, KalVista’s 2025 WO filings explicitly construct patent claims around the combination of oral sebetralstat as on-demand treatment in patients concurrently receiving prophylaxis with FXIIa inhibitors (garadacimab) or other long-acting biologics — positioning sebetralstat as a complementary layer within a prophylaxis-plus-on-demand treatment paradigm rather than a standalone alternative. Verseon Corporation holds an independent small molecule scaffold (pyridone-substituted pyrazolyl compounds) representing a distinct chemical series with potential pKal activity.

Combination Regimen IP: The Emerging Battleground

Claims filed by KalVista explicitly covering use of oral pKal inhibitors in patients on FXIIa inhibitor prophylaxis, and Alnylam’s multi-target RNAi compositions simultaneously silencing KLKB1, F12, and KNG1, signal that combination or layered therapy claims will be a contested IP frontier as the pipeline matures. As clinical differentiation increasingly requires additive mechanism justification — particularly as multiple prophylactic agents compete in the same patient population — combination use patents will become strategically significant for both commercial exclusivity and licensing leverage. C1-INH replacement products (Cinryze, Ruconest, Berinert, Haegarda, covered by CSL Behring GmbH pharmacokinetic/pharmacodynamic modeling patents) serve as comparator reference points in newer modality filings, reflecting the established therapeutic baseline against which all pipeline assets are positioned.

“Gene therapy and RNA activation remain the only approaches targeting root-cause restoration of C1-INH — aiming to restore, rather than bypass, the deficient protein — making them potentially curative, but the absence of clinical signals in retrieved results suggests substantial development risk remains.”

The assignee landscape reflects the commercially mature and competitive nature of HAE therapeutics: retrieved results are overwhelmingly patent-driven, with a single academic literature record (University of California San Diego, a 2010 CME symposium summary). Orchard Therapeutics (Europe) Limited and Ractigen Therapeutics represent the smallest but most forward-looking portfolios, with Orchard’s cell-based C1-INH expression approach and Ractigen’s saRNA SERPING1 upregulation filing representing the only programs in this dataset that target restoration of the deficient inhibitor rather than suppression of downstream pathway components. The EMA‘s advanced therapy medicinal products (ATMP) framework and FDA‘s Regenerative Medicine Advanced Therapy (RMAT) designation provide regulatory pathways that could accelerate development of these cell and gene therapy approaches if clinical proof-of-concept is established.